Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.

Similar Items

• European priority review vouchers for neglected disease product development
  by: David B Ridley, et al.
  Published: (2024-01-01)
• Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
  by: Catherine Mease, et al.
  Published: (2024-02-01)
• Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
  by: Catherine Mease, et al.
  Published: (2024-03-01)
• Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
  by: Olliaro, P, et al.
  Published: (2018)
• Incentivizing organ donation with priority voucher : an experimental study
  by: Wang, Song
  Published: (2019)